Pathophysiology: CSF Drainage and Glymphatic Clearance

1 Wall et al. 2014 β€” IIHTT: Acetazolamide RCT for Idiopathic Intracranial Hypertension

Full Citation:: Wall M, Kupersmith MJ, Kieburtz KD, et al. The Idiopathic Intracranial Hypertension Treatment Trial: Clinical Profile at Baseline. JAMA. 2014;311(16):1641–1651. DOI:: 10.1001/jama.2014.3312 PMID:: 24756514 Published:: 2014 Study Design:: Multicenter RCT, 38 sites, n=165 IIH patients, 6 months Intervention:: Maximally tolerated acetazolamide (up to 4 g/day) vs placebo + low-sodium diet Key Findings::

- Acetazolamide improved visual field function (+0.71 dB, p=.050)
- Reduced papilledema (p\<.001)
- Improved vision-related QoL (p=.003)
- Weight loss -4.05 kg (p\<.001)

Relevance:: Landmark Class I evidence establishing acetazolamide as first-line IIH therapy. Demonstrates that CA inhibition reduces CSF production, directly supporting the β€œreduce input” side of the combined hypothesis. Establishes mechanistic basis for acetazolamide use in CSF dynamics disorders. Limitations:: Modest effect size on visual field; 50% experienced treatment-limiting adverse effects (paresthesias, dysgeusia); benefit may partially reflect weight loss; nearly all participants were women (limiting generalizability). Certainty Assessment::

- *Quality:* High (Class I RCT, multicenter, JAMA)
- *Sample:* Adequate (n=165)
- *Replication:* Landmark trial; standard of care
- *Score:* 0.90

2 Mitchell et al. 2025 β€” Head-to-Head ICP Drug Comparison (CRITICAL NEGATIVE)

Full Citation:: Mitchell JL, Bhatt N, Weckerle C, Wicklund M, Smith M, Pott J, Bodle JD. A randomized sequential crossover study comparing acetazolamide, amiloride, furosemide, spironolactone, and topiramate in idiopathic intracranial hypertension. Headache. 2025;65(2):258–268. DOI:: 10.1111/head.14897 PMID:: 39853738 Published:: 2025 Study Design:: Randomized sequential crossover, n=14 IIH patients, telemetric ICP monitoring, 2-week treatment periods Key Findings::

- All drugs reduced ICP marginally: acetazolamide -3.3 mmHg, furosemide -3.0, spironolactone -2.7, topiramate -2.3 (no significant between-drug difference)
- Side effects common: acetazolamide 100\%, topiramate 93\%
- *Both acetazolamide and topiramate worsened fluid cognition (p=0.057 and 0.061 respectively)*

Relevance:: Critical negative finding for ME/CFS application. CA inhibitors impaired cognition at ICP-reducing doses. ME/CFS patients already have cognitive dysfunction; this is a serious safety barrier. First head-to-head comparison with objective telemetric ICP measurement. Directly challenges the safety of the combined hypothesis. Limitations:: Small sample (n=14), not powered for between-drug differences, unblinded design for individual drugs. Certainty Assessment::

- *Quality:* Medium (novel design with objective ICP measurement, but small n, unblinded)
- *Sample:* Small (n=14)
- *Replication:* Not yet replicated; unique telemetric ICP design
- *Score:* 0.70

Safety Concern:: MAJOR β€” cognitive worsening at effective ICP-reducing doses directly challenges safety for ME/CFS.

3 Goyal & Zarroli 2023 β€” Topiramate as Alternative First-Line for IIH

Full Citation:: Goyal A, Zarroli K. Topiramate: An Alternative First-Line Agent for the Treatment of Idiopathic Intracranial Hypertension. Medicine. 2023;102(42):e35545. DOI:: 10.1097/MD.0000000000035545 PMID:: 37861536 Published:: 2023 Study Design:: Literature review Key Findings:: Topiramate has multiple mechanisms relevant to IIH: CA inhibition (reduces ICP), weight loss promotion, migraine prophylaxis. Safety profile comparable or superior to acetazolamide. Weight loss benefit addresses obesity-IIH overlap. Relevance:: Supports topiramate as rational alternative/complement to acetazolamide, particularly for patients with comorbid migraine (common in ME/CFS). Additional TRPV1/mast cell mechanism (Souza2024) may provide dual therapeutic action. Limitations:: Review article only; no direct comparison data; limited RCT evidence for topiramate in IIH. Certainty Assessment::

- *Quality:* Low-medium (review article, Medicine journal)
- *Replication:* No primary data
- *Score:* 0.55

4 Wang et al. 2022 β€” IIH Comprehensive Review

Full Citation:: Wang MTM, Bhatti MT, Danesh-Meyer HV. Idiopathic intracranial hypertension: a review. J Clin Neurosci. 2022;95:172–179. DOI:: 10.1016/j.jocn.2021.11.029 PMID:: 34929642 Published:: 2022 Study Design:: Narrative review Key Findings:: IIH pathophysiology involves CSF dynamics dysregulation and venous sinus pressure. IIHTT provides Class I evidence for acetazolamide. Emerging metabolic/hormonal targets discussed. Relevance:: Provides mechanistic context for CA inhibitor use in CSF dynamics disorders. Useful background for understanding the β€œreduce input” side of the combined hypothesis. Limitations:: Narrative review, no primary data. Certainty Assessment::

- *Quality:* Low-medium (narrative review)
- *Score:* 0.55

5 Medow & Stewart 2024 β€” Acetazolamide in ME/CFS with Orthostatic Intolerance (NEGATIVE)

Full Citation:: Medow MS, Stewart JM. Effects of acetazolamide and phenylephrine on neurocognitive function during head-up tilt in ME/CFS with POTS. Am J Physiol Regul Integr Comp Physiol. 2024;326(6):R599–R608. DOI:: 10.1152/ajpregu.00071.2024 PMID:: 38682242 Published:: 2024 Study Design:: Controlled experimental physiology study, n=15 ME/CFS+POTS, n=11 controls Intervention:: CO2, acetazolamide, and phenylephrine tested during head-up tilt Key Findings::

- *Acetazolamide had NO effect on neurocognitive function during orthostatic challenge in ME/CFS*
- Only phenylephrine improved upright N-back performance (ME/CFS+PE=65.6\% vs control 56.9\%)
- Acetazolamide did not improve cerebral autoregulation (phase synchronization index)

Relevance:: Directly challenges the hypothesis for ME/CFS application. In ME/CFS with OI/POTS, acetazolamide does not improve the orthostatic cognitive impairment the hypothesis targets. Only tested acute effects; chronic CSF volume reduction might differ. Limitations:: Small sample, acute (not chronic) administration, phenylephrine not viable long-term treatment. Certainty Assessment::

- *Quality:* Medium-high (controlled design, directly relevant population, AJP journal)
- *Sample:* Small (n=15 ME/CFS+POTS, n=11 controls)
- *Replication:* Not yet replicated; unique ME/CFS-specific acetazolamide study
- *Score:* 0.75

Safety Concern:: MODERATE β€” ineffective for targeted symptom; Mitchell2025 adds cognitive worsening risk.

6 Riste et al. 2025 β€” Self-Help Perrin Technique RCT for Long COVID

Full Citation:: Riste L, Perrin R, Mulholland T, Hann M, McDonald O, Heald A. A feasibility randomized controlled trial of a self-help Perrin Technique intervention for Long COVID. Infect Dis Ther. 2026;15(2):577–589. DOI:: 10.1007/s40121-025-01287-z PMID:: 41442105 Published:: 2026 Study Design:: Feasibility RCT, n=100 Long COVID patients, self-help Perrin Technique vs wait-list control, 3-month follow-up Intervention:: Self-massage, mobility exercises, breathing exercises, cold/warm packs Key Findings::

- Chalder Fatigue Questionnaire improvement in intervention group at 3 months (p=0.01)
- High recruitment rate (90.6\%), 79.3\% follow-up
- Participants found intervention onerous but were keen to engage

Relevance:: First RCT evidence supporting Perrin-derived lymphatic drainage approach for fatigue. Supports the β€œincrease output” side of the combined hypothesis. Applicable to both Long COVID and ME/CFS. Limitations:: Feasibility study (not powered for efficacy); self-help not practitioner-administered; no ME/CFS-specific data; no CSF/glymphatic measurement; conflict of interest (Perrin developed the intervention); large control group improvement may confound results. Certainty Assessment::

- *Quality:* Low-medium (feasibility RCT, conflict of interest)
- *Sample:* Adequate for feasibility (n=100), underpowered for efficacy
- *Replication:* First RCT; not yet replicated
- *Score:* 0.55

7 Midtlien et al. 2024 β€” CTD + CVD + IIH Clinical Phenotype

Full Citation:: Midtlien JP, Linde M, Aamodt AH, et al. Clinical features of patients with connective tissue disorders and cerebral venous disease. Front Neurol. 2024;15:1305972. DOI:: 10.3389/fneur.2023.1305972 PMID:: 38269002 Published:: 2024 Study Design:: Retrospective single-center review, n=86 patients with CTD + cerebral venous outflow disorders Key Findings::

- 55\% had EDS diagnosis
- 55.8\% had POTS
- 51.2\% had CSF leaks
- 37.2\% had CCI
- 25.6\% had MCAS
- Despite lower opening pressures than classic IIH, headache severity and QoL were comparable, suggesting *hypersensitivity to intracranial pressures*
- 87.2\% had medication allergies; 19.8\% allergic to surgical tape

Relevance:: Critically important for the hypothesis. Establishes a conserved clinical phenotype of CTD+CVD+IIH+CCI+POTS+MCAS β€” precisely the patient population where combined CA inhibitor + lymphatic drainage would be considered. The pressure hypersensitivity finding suggests lower drug doses may be needed than classical IIH protocols. Largest series of this phenotype to date. Limitations:: Retrospective, single center, no control group, potential selection bias from tertiary referral center. Certainty Assessment::

- *Quality:* Medium (largest series of this phenotype, retrospective design)
- *Sample:* Moderate (n=86)
- *Replication:* Not yet independently replicated; consistent with Bragee2020 ME/CFS findings (78\% intracranial hypertension signs in n=229)
- *Score:* 0.70

8 McGrath et al. 2026 β€” Bimodal ME/CFS Onset Age Peaks

Full Citation:: McGrath SJ, Hillier CB, Dibble JJ, Schei T, Angelsen A, Ryback AA. Incidence age is bimodal for myalgic encephalomyelitis/chronic fatigue syndrome, with higher severity burden for early onset disease. Oxford Open Immunology. 2026;7(1):iqag007. DOI:: 10.1093/oxfimm/iqag007 PMID:: 41983041 PMCID:: PMC13070794 Published:: 2026 Study Design:: Cross-sectional survey analysis (EMEA survey, n=9,380) with statistical validation (Hartigan’s Dip Test, Gaussian mixture models) and independent replication in DecodeME subset (n=6,455) Key Findings::

- Early onset peak: mean 16.0 years (SD 4.3); late onset peak: mean 36.6 years (SD 10.5)
- Dip test highly significant for Norway and all-other-countries combined ($p lt 2 \times 10^{-16}$)
- Six of nine non-Norway countries individually significant
- Replicated in DecodeME (early peak ~18.8, late peak ~40.1)
- Infection as trigger: 57% early vs.\ 47% late onset ($p = 2.1 \times 10^{-13}$)
- Infectious mononucleosis specifically: OR 2.32 for early onset ($p = 2.4 \times 10^{-24}$)
- Severity: early onset OR 2.15 for severe/very severe ($p lt 2 \times 10^{-16}$)
- Familial clustering: OR 1.43 for early onset with affected first-degree relative ($p = 4.4 \times 10^{-7}$)
- No significant gender difference between peaks ($p = 0.21$)

Conclusion:: ME/CFS has two robust onset age peaks (~16 and ~37 years) replicated across multiple European countries and an independent dataset. Early onset is associated with infectious triggers (especially IM), greater severity, and familial clustering, suggesting distinct biological substrates for the two peaks. Limitations:: Self-report survey data; selection bias (promoted by ME organisations); only diagnosed patients; onset age from recall; DecodeME onset age approximated (Β±2.5 year error). Cross-sectional design cannot establish causation for observed associations. Certainty Assessment::

- *Quality:* Medium (self-report; moderate journal; but large n and independent replication)
- *Sample:* Large (n=9,380 + 6,455 validation)
- *Replication:* Partially replicated (DecodeME subset with different methodology)
- *Score:* 0.65

9 Bakken et al. 2014 β€” Norwegian Registry Bimodal Onset (Precursor)

Full Citation:: Bakken IJ, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Trogstad L, HΓ₯berg SE, Magnus P. Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008–2012. BMC Medicine. 2014;12:167. DOI:: 10.1186/s12916-014-0167-5 PMID:: 25274261 PMCID:: PMC4232642 Published:: 2014 Study Design:: Population-based registry study using Norwegian patient register (hospital and specialist outpatient records), entire population of Norway 2008–2012 Key Findings::

- G93.3 diagnoses most frequent in age groups 10--19 and 30--39 years
- Higher proportion of females in second peak
- First demonstration of bimodal age distribution in ME/CFS

Conclusion:: ME/CFS shows two distinct age peaks at diagnosis in a population-based registry, establishing the bimodal pattern before the McGrath et al. survey-based confirmation. Limitations:: Age at diagnosis (not onset); specialist/hospital records only (misses primary care); diagnostic delay biases age estimates toward older ages. Certainty Assessment::

- *Quality:* Medium-High (population-based registry, but diagnosis not onset)
- *Sample:* Large (n=5,809)
- *Replication:* Replicated by McGrath et al.\ 2026 using survey onset data
- *Score:* 0.70

10 Jin et al. 2019 β€” Vitiligo Bimodal Onset Reveals MHC Class II Haplotype

Full Citation:: Jin Y, Roberts GHL, Ferrara TM, et al. Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. Nature Communications. 2019;10:391. DOI:: 10.1038/s41467-019-08337-4 PMID:: 30674883 PMCID:: PMC6344500 Published:: 2019 Study Design:: GWAS with subgroup analysis by age of onset (n=4,523 vitiligo cases) Key Findings::

- Vitiligo age-of-onset is bimodal: early onset mean 10.3 years (38.4%), late onset mean 34.0 years (61.6%)
- Early-onset subgroup: novel MHC class II association with rs145954018 indel
- High-risk haplotype rs145954018del-rs9271597A: OR = 8.10 ($p = 2.40 \times 10^{-86}$)
- Haplotype upregulates HLA-DQB1 expression in monocytes and dendritic cells

Conclusion:: Demonstrates that bimodal disease onset can reveal distinct genetic architectures. The early-onset vitiligo subgroup has a specific HLA association with OR > 8, providing the strongest precedent for using bimodal onset analysis to identify biological subtypes. Limitations:: European ancestry only; GWAS design cannot prove causation. Certainty Assessment::

- *Quality:* High (top journal, large n, rigorous methodology)
- *Sample:* Large (n=4,523)
- *Replication:* GWAS replicated; functional validation of HLA expression
- *Score:* 0.80

11 Katz et al. 2009 β€” CFS After Infectious Mononucleosis in Adolescents

Full Citation:: Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics. 2009;124(1):189–93. DOI:: 10.1542/peds.2008-1879 PMID:: 19564299 Published:: 2009 Study Design:: Prospective cohort study, 2-year follow-up after acute IM in adolescents Key Findings::

- 13% of adolescents met CFS criteria 6 months after acute IM
- IM is a specific risk factor for CFS in adolescents
- Onset in adolescence consistent with early ME/CFS peak

Conclusion:: Infectious mononucleosis is a major driver of the early-onset ME/CFS peak, with ~13% of affected adolescents progressing to CFS. Limitations:: Small sample; single centre. Certainty Assessment::

- *Quality:* Medium (prospective design, peer-reviewed, but small n)
- *Sample:* Small (n~200)
- *Replication:* Consistent with McGrath 2026 DecodeME finding (IM OR 2.32 for early onset)
- *Score:* 0.55

12 Grotmol et al. 2011 β€” Hodgkin Lymphoma Bimodal Frailty Model

Full Citation:: Grotmol T, Bray F, Holte H, Klepp O, Foss Γ…, Aalen OO. Frailty modeling of the bimodal age-incidence of Hodgkin lymphoma in the Nordic countries. Cancer Epidemiology, Biomarkers & Prevention. 2011;20(7):1350–7. DOI:: 10.1158/1055-9965.EPI-10-1014 PMID:: 21558495 Published:: 2011 Study Design:: Frailty modeling of population-based Nordic cancer registry data Key Findings::

- HL age-incidence data consistent with bimodal frailty model
- Subgroups with distinct aetiologies (EBV-associated young-adult vs.\ elderly HL)

Conclusion:: Demonstrates statistical methodology for establishing bimodal disease patterns and supports the general principle that bimodal onset reflects distinct disease subtypes. Limitations:: Modeling study; no individual-level data on triggers. Certainty Assessment::

- *Quality:* Medium (population-based data, peer-reviewed, modeling approach)
- *Sample:* Large (Nordic cancer registries)
- *Replication:* Standard methodology applied to well-established bimodal pattern
- *Score:* 0.60